Piperacillin Inj Rx
Generic Name and Formulations:
Piperacillin sodium 2g, 3g, 4g; per vial; pwd for IM or IV inj after reconstitution; IV infusion after reconstitution and dilution; sodium content 42.5mg/g piperacillin sodium.
Various generic manufacturers
Indications for Piperacillin Inj:
Serious susceptible infections, including lower respiratory tract, intraabdominal, septicemia, skin and skin structure, bone and joint, UTIs, gynecological infections, and uncomplicated gonoccocal urethritis. Surgical prophylaxis in intraabdominal (GI and biliary) procedures, vaginal and abdominal hysterectomy, and cesarean section.
Give by IM inj into upper outer quadrant of buttock; or IV inj over 3–5 minutes; or IV infusion over 20–30 minutes. Max dose: 24g/day. IM inj: max 2g per injection site. May give 1g probenecid orally ½ hour prior to inj. Serious infections: 12–18g/day IV (200–300mg/kg/day) in divided doses every 4–6 hours. Complicated UTIs: 8–16g/day IV (125–200mg/kg/day) in divided doses every 6–8 hours. Uncomplicated UTIs and community-acquired pneumonia: 6–8g/day IM or IV (100–125mg/kg/day) in divided doses every 6–12 hours. Uncomplicated gonorrhea infections: 2g IM once as a single dose. All: treat for 7–10 days; gynecological infections: 3–10 days; Streptococcus pyogenes infections: at least 10 days. Acute infections: continue therapy 48–72 hours after patient becomes asymptomatic. Prophylaxis, renal impairment, or hemodialysis: see literature.
Beta-lactam allergy including cephalosporins.
Renal impairment. Salt-restricted. Monitor renal, hepatic, hematopoietic function in prolonged use. Discontinue if bleeding disorder occurs. Cystic fibrosis (increased fever/rash risk). Gonorrhea infections: do serologic test for syphilis at baseline and 3 months after therapy. Pregnancy (Cat.B). Nursing mothers.
Potentiated by probenecid. Antagonizes aminoglycosides. May potentiate non-depolarizing muscle relaxants (eg, vercuronium). Monitor methotrexate, heparin, anticoagulants. May cause false (+) with Clinitest, Benedict's or Fehling's soln, Coomb's test.
Inj site reactions, GI disturbances, rash (may be severe, eg, Stevens-Johnson syndrome), headache, dizziness, fatigue, seizures, renal impairment, anaphylaxis, blood dyscrasias, bleeding.
Formerly known under the brand name Pipracil.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC